menu search

Day one announces new firefly-1 data for tovorafenib (day101) and initiation of rolling nda submission to fda for relapsed or progressive pediatric low-grade glioma

Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to ...

June 4, 2023, 4:45 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Elys game technology to present company business update and 2023 earnings guidance video conference

Management to discuss initiation of US facing mobile operations, infrastructure installations, Q1-’23...

May 31, 2023, 8:15 pm

Spexis provides business update and announces financial results for the full year 2022

Ad hoc announcement pursuant to Art. 53 LR USD 4.5 million capital commitment from SPRIM Global Investments to enable ...

May 30, 2023, 5:15 am

Paycom software: remains a core holding on initiation of a dividend

Paycom remains among a small group of highly profitable, high-growth cloud software companies. The valuation today is reasonable, and more so today th...

May 21, 2023, 11:36 am

Usha resources resumes drilling activities at jackpot lake lithium brine project

Usha Resources Ltd (TSX-V:USHA) has announced the resumption of drilling activities at its flagship Jackpot Lake Lithium Brine Project and the ...

May 18, 2023, 8:04 am

Exscientia's ai-powered drug discovery platform is the future of precision medicine

Exscientia's AI-driven drug discovery platform has positioned the company at the forefront of precision medicine, revolutionizing the way new therapie...

May 18, 2023, 1:44 am

Open banking: the uk shows promise, but struggle remains

Seven million users and counting, that’s the current state of play for the UK’s open banking usage. To me, it’s a good number, one that shows th...

May 17, 2023, 10:45 am


Search within

Pages Search Results: